Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Siderocalin (Lipocalin-2, NGAL, 24p3) is a mammalian immune protein of the lipocalin family, playing a vital role in host defense by binding and sequestering iron-chelating siderophores. This activity restricts iron availability to invading bacteria, acting as a bacteriostatic mechanism in the innate immune response. The protein is structurally characterized by a cup-shaped binding domain ("calyx") with three positively charged pockets that accommodate the catecholate groups of siderophores, particularly those like enterobactin from *Escherichia coli* and bacillibactin from *Bacillus anthracis*. Siderocalin can also bind a variety of other ferric complexes and is found in monomeric, dimeric, or trimeric forms in plasma. Its selectivity is defined by shape and charge complementarity with specific bacterial siderophores, and bacteria may evade its binding by chemically modifying their siderophores. Siderocalin is used clinically as a biomarker of kidney injury, and altered levels are associated with infection, inflammation, and cancer prognosis. Although not currently a direct drug target, its mechanism of iron sequestration is a focus of research in antimicrobial and diagnostic development.
Sequestration of iron by binding ferric siderophore complexes, inhibiting bacterial iron acquisition Potential anti-infective mechanisms by starving pathogens of iron
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Siderocalin (NGAL; Scn).